Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?

por Talamonti, M., Tofani, L., Bianchi, L., Galluzzo, M.
Publicado 2020

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date

por Galluzzo, M, D’Adamio, S, Massaro, A, Piccolo, A, Bianchi, L, Talamonti, M
Publicado 2019

Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab

por Signa, S., Campione, E., Rusmini, M., Chiesa, S., Grossi, A., Omenetti, A., Caorsi, R., Viglizzo, G. M., Galluzzo, M., Bianchi, L., Talamonti, M., Orlandi, A., Martini, A., Ceccherini, I., Gattorno, M.
Publicado 2019

Response to IL‐17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein‐coding and untranslated regions of the IL‐17A gene: results from a...

por van Vugt, L.J., van den Reek, J.M.P.A., Meulewaeter, E., Hakobjan, M., Heddes, N., Traks, T., Kingo, K., Galluzzo, M., Talamonti, M., Lambert, J., Coenen, M.J.H., de Jong, E.M.G.J.
Publicado 2019